News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Yakult Honsha, Terumo To Co-develop Liposomal Formulation Of Irinotecan
May 22, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo, May 19, 2006 (JCN) - Yakult Honsha announced on May 18 that it will develop a liposomal formulation of irinotecan, a kind of anticancer agent, with Terumo. A development code for the agent is IHL-305.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Asia
MORE ON THIS TOPIC
Collaboration
CRISPR Expands Focus, Pays Up To $95M in Sirius’ siRNA Pact
May 20, 2025
·
2 min read
·
Tristan Manalac
Cancer
Pfizer Puts $6B on the Line for 3SBio’s PD-1/VEGF Antibody
May 20, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan
May 19, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
BioMarin Expands Enzyme Expertise With $270M Inozyme Buy
May 16, 2025
·
2 min read
·
Tristan Manalac
